| ［1］ |
中国中西医结合学会皮肤性病专业委员会色素病学组. 白癜风诊疗共识（2021版）［J］. 中华皮肤科杂志, 2021,54（2）:105⁃109. doi: 10.35541/cjd.20200785.
|
| ［2］ |
Taieb A, Alomar A, Böhm M, et al. Guidelines for the management of vitiligo: the European Dermatology Forum consensus［J］. Br J Dermatol, 2013,168（1）:5⁃19. doi: 10.1111/j.1365⁃2133.2012.11197.x.
|
| ［3］ |
Mohammad TF, Al⁃Jamal M, Hamzavi IH, et al. The Vitiligo Working Group recommendations for narrowband ultraviolet B light phototherapy treatment of vitiligo［J］. J Am Acad Dermatol, 2017,76（5）:879⁃888. doi: 10.1016/j.jaad.2016.12.041.
|
| ［4］ |
中华中医药学会皮肤科分会. 白癜风中医治疗专家共识［J］. 中国中西医结合皮肤性病学杂志, 2017,16（2）:191⁃192. doi: 10.3969/j.issn.1672⁃0709.2017.02.037.
|
| ［5］ |
中国中西医结合学会皮肤性病专业委员会皮肤外科学组. 白癜风外科治疗共识（2012）［J］. 中华皮肤科杂志, 2012,45（10）:691⁃692. doi: 10.3760/cma.j.issn.0412⁃4030.2012.10.001.
|
| ［6］ |
Bae JM, Jeong KH, Choi CW, et al. Development of evidence⁃based consensus on critical issues in the management of patients with vitiligo: a modified Delphi study［J］. Photodermatol Photoimmunol Photomed, 2021,37（1）:3⁃11. doi: 10.1111/phpp. 12598.
|
| ［7］ |
Gawkrodger DJ, Ormerod AD, Shaw L, et al. Guideline for the diagnosis and management of vitiligo［J］. Br J Dermatol, 2008,159（5）:1051⁃1076. doi: 10.1111/j.1365⁃2133.2008.08881.x.
|
| ［8］ |
Rodrigues M, Ezzedine K, Hamzavi I, et al. Current and emerging treatments for vitiligo［J］. J Am Acad Dermatol, 2017,77（1）:17⁃29. doi: 10.1016/j.jaad.2016.11.010.
|
| ［9］ |
Oiso N, Suzuki T, Wataya⁃Kaneda M, et al. Guidelines for the diagnosis and treatment of vitiligo in Japan［J］. J Dermatol, 2013,40（5）:344⁃354. doi: 10.1111/1346⁃8138.12099.
|
| ［10］ |
Njoo MD, Das PK, Bos JD, et al. Association of the Köbner phenomenon with disease activity and therapeutic responsiveness in vitiligo vulgaris［J］. Arch Dermatol, 1999,135（4）:407⁃413. doi: 10.1001/archderm.135.4.407.
|
| ［11］ |
Hamzavi I, Jain H, McLean D, et al. Parametric modeling of narrowband UV⁃B phototherapy for vitiligo using a novel quantitative tool: the Vitiligo Area Scoring Index［J］. Arch Dermatol, 2004,140（6）:677⁃683. doi: 10.1001/archderm.140.6. 677.
|
| ［12］ |
Radtke MA, Schäfer I, Gajur A, et al. Willingness⁃to⁃pay and quality of life in patients with vitiligo［J］. Br J Dermatol, 2009,161（1）:134⁃139. doi: 10.1111/j.1365⁃2133.2009.09091.x.
|
| ［13］ |
Boguniewicz M, Alexis AF, Beck LA, et al. Expert perspectives on management of moderate⁃to⁃severe atopic dermatitis: a multidisciplinary consensus addressing current and emerging therapies［J］. J Allergy Clin Immunol Pract, 2017,5（6）:1519⁃1531. doi: 10.1016/j.jaip.2017.08.005.
|
| ［14］ |
Kogan N, Raimondo N, Gusis SE, et al. Latin American clinical practice guidelines on the systemic treatment of psoriasis SOLAPSO ⁃ Sociedad Latinoamericana de Psoriasis （Latin American Psoriasis Society）［J］. Int J Dermatol, 2019,58 Suppl 1:4⁃28. doi: 10.1111/ijd.14471.
|
| ［15］ |
Feily A. Vitiligo Extent Tensity Index （VETI） score: a new definition, assessment and treatment evaluation criteria in vitiligo［J］. Dermatol Pract Concept, 2014,4（4）:81⁃84. doi: 10. 5826/dpc.0404a18.
|
| ［16］ |
Taïeb A, Picardo M. The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force［J］. Pigment Cell Res, 2007,20（1）:27⁃35. doi: 10.1111/j.1600⁃0749. 2006.00355.x.
|
| ［17］ |
van Geel N, Lommerts J, Bekkenk M, et al. Development and validation of the Vitiligo Extent Score （VES）: an International Collaborative Initiative［J］. J Invest Dermatol, 2016,136（5）:978⁃984. doi: 10.1016/j.jid.2015.12.040.
|
| ［18］ |
Hartmann A, Bröcker EB, Hamm H. Occlusive treatment enhances efficacy of tacrolimus 0.1% ointment in adult patients with vitiligo: results of a placebo⁃controlled 12⁃month prospective study［J］. Acta Derm Venereol, 2008,88（5）:474⁃479. doi: 10.2340/00015555⁃0464.
|
| ［19］ |
贾苇雪, 李诚让. 系统应用糖皮质激素治疗白癜风［J］. 国际皮肤性病学杂志, 2014,40（2）:83⁃86. doi: 10.3760/cma.j.issn. 1673⁃4173.2014.02.003.
|
| ［20］ |
Migayron L, Boniface K, Seneschal J. Vitiligo, from physiopathology to emerging treatments: a review［J］. Dermatol Ther （Heidelb）, 2020,10（6）:1185⁃1198. doi: 10.1007/s13555⁃020⁃00447⁃y.
|
| ［21］ |
Lim HW, Grimes PE, Agbai O, et al. Afamelanotide and narrowband UV⁃B phototherapy for the treatment of vitiligo: a randomized multicenter trial［J］. JAMA Dermatol, 2015,151（1）:42⁃50. doi: 10.1001/jamadermatol.2014.1875.
|
| ［22］ |
Nguyen S, Chuah SY, Fontas E, et al. Atorvastatin in combination with narrowband UV⁃B in adult patients with active vitiligo: a randomized clinical trial［J］. JAMA Dermatol, 2018,154（6）:725⁃726. doi: 10.1001/jamadermatol.2017.6401.
|
| ［23］ |
Vanderweil SG, Amano S, Ko WC, et al. A double⁃blind, placebo⁃controlled, phase⁃II clinical trial to evaluate oral simvastatin as a treatment for vitiligo［J］. J Am Acad Dermatol, 2017,76（1）:150⁃151.e3. doi: 10.1016/j.jaad.2016.06.015.
|
